Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
10 2021
Historique:
received: 03 09 2020
revised: 26 02 2021
accepted: 30 04 2021
pubmed: 12 5 2021
medline: 15 3 2022
entrez: 11 5 2021
Statut: ppublish

Résumé

Little is known of the geospatial architecture of individual cell populations in lung adenocarcinoma (LUAD) evolution. Here, we perform single-cell RNA sequencing of 186,916 cells from five early-stage LUADs and 14 multiregion normal lung tissues of defined spatial proximities from the tumors. We show that cellular lineages, states, and transcriptomic features geospatially evolve across normal regions to LUADs. LUADs also exhibit pronounced intratumor cell heterogeneity within single sites and transcriptional lineage-plasticity programs. T regulatory cell phenotypes are increased in normal tissues with proximity to LUAD, in contrast to diminished signatures and fractions of cytotoxic CD8

Identifiants

pubmed: 33972311
pii: 2159-8290.CD-20-1285
doi: 10.1158/2159-8290.CD-20-1285
pmc: PMC8487926
mid: NIHMS1702957
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2506-2523

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL130129
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : U2C CA233238
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA205608
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL153511
Pays : United States
Organisme : NIH HHS
ID : S10 OD024977
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : CSRD VA
ID : I01 CX000345
Pays : United States

Informations de copyright

©2021 American Association for Cancer Research.

Références

Dev Cell. 2018 Mar 26;44(6):653-654
pubmed: 29587138
Science. 2014 Oct 10;346(6206):256-9
pubmed: 25301631
Nat Med. 2020 Feb;26(2):259-269
pubmed: 32042191
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Immunol Today. 1997 Jun;18(6):292-9
pubmed: 9190116
Nature. 2019 Aug;572(7769):392-396
pubmed: 31367043
Nature. 2014 May 15;509(7500):371-5
pubmed: 24739965
Cancer Res. 2020 Nov 15;80(22):4888-4891
pubmed: 33023945
Nature. 2019 Feb;566(7745):496-502
pubmed: 30787437
Nat Biotechnol. 2015 May;33(5):495-502
pubmed: 25867923
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Clin Cancer Res. 1999 Aug;5(8):2025-34
pubmed: 10473082
Nat Methods. 2019 Jan;16(1):43-49
pubmed: 30573817
Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20545-20555
pubmed: 31548395
Curr Opin Syst Biol. 2017 Apr;2:1-8
pubmed: 30603736
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Immunol Rev. 2011 May;241(1):104-18
pubmed: 21488893
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Immunity. 2018 May 15;48(5):923-936.e4
pubmed: 29752065
Cell Rep. 2019 Mar 12;26(11):2942-2954.e5
pubmed: 30865885
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
Front Immunol. 2020 Feb 11;11:159
pubmed: 32117295
Nat Methods. 2019 Dec;16(12):1289-1296
pubmed: 31740819
Nat Rev Cancer. 2018 Jun;18(6):359-376
pubmed: 29700396
Nature. 2016 Nov 10;539(7628):309-313
pubmed: 27806376
Nat Commun. 2020 May 8;11(1):2285
pubmed: 32385277
Nature. 2014 Mar 13;507(7491):190-4
pubmed: 24499815
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6409-E6417
pubmed: 27702896
Nat Rev Cancer. 2014 Aug;14(8):535-46
pubmed: 25056707
Cell. 2020 Sep 3;182(5):1232-1251.e22
pubmed: 32822576
Cell Mol Immunol. 2019 Jan;16(1):6-18
pubmed: 29628498
Am J Respir Crit Care Med. 2015 Feb 15;191(4):437-47
pubmed: 25536148
Lancet. 2011 Nov 12;378(9804):1727-40
pubmed: 21565398
Immunity. 2008 Jan;28(1):88-99
pubmed: 18191593
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Nature. 2018 Aug;560(7718):377-381
pubmed: 30069046
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
J Thorac Oncol. 2011 Jan;6(1):209-17
pubmed: 21107292
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
Mol Cell. 2013 Apr 25;50(2):185-99
pubmed: 23523371
Nat Med. 2018 Aug;24(8):1277-1289
pubmed: 29988129
Am J Respir Crit Care Med. 2021 Jan 1;203(1):90-101
pubmed: 32730093
Nature. 2018 Aug;560(7718):319-324
pubmed: 30069044
J Biol Chem. 2002 May 10;277(19):17125-38
pubmed: 11886848
Cancer Res. 2002 Apr 15;62(8):2370-7
pubmed: 11956099

Auteurs

Ansam Sinjab (A)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Guangchun Han (G)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Warapen Treekitkarnmongkol (W)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Kieko Hara (K)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Patrick M Brennan (PM)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Minghao Dang (M)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Dapeng Hao (D)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Ruiping Wang (R)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Enyu Dai (E)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Hitoshi Dejima (H)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Jiexin Zhang (J)

Department of Bioinformatics and Computer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Elena Bogatenkova (E)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Beatriz Sanchez-Espiridion (B)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Kyle Chang (K)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Danielle R Little (DR)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Samer Bazzi (S)

Faculty of Arts and Sciences, University of Balamand, Koura, Lebanon.

Linh M Tran (LM)

Department of Medicine, University of California, Los Angeles, Los Angeles, California.

Kostyantyn Krysan (K)

Department of Medicine, University of California, Los Angeles, Los Angeles, California.

Carmen Behrens (C)

Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Dzifa Y Duose (DY)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Edwin R Parra (ER)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Maria Gabriela Raso (MG)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Luisa M Solis (LM)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Junya Fukuoka (J)

Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Jianjun Zhang (J)

Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Boris Sepesi (B)

Department of Cardiovascular and Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Tina Cascone (T)

Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Lauren Averett Byers (LA)

Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Don L Gibbons (DL)

Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Jichao Chen (J)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Seyed Javad Moghaddam (SJ)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Edwin J Ostrin (EJ)

Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Daniel Rosen (D)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas.

John V Heymach (JV)

Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Paul Scheet (P)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Steven M Dubinett (SM)

Department of Medicine, University of California, Los Angeles, Los Angeles, California.

Junya Fujimoto (J)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Ignacio I Wistuba (II)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Christopher S Stevenson (CS)

Lung Cancer Initiative at Johnson and Johnson, Boston, Massachusetts.

Avrum Spira (A)

Lung Cancer Initiative at Johnson and Johnson, Boston, Massachusetts.
Section of Computational Biomedicine, Boston University, Boston, Massachusetts.

Linghua Wang (L)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. hkadara@mdanderson.org lwang22@mdanderson.org.

Humam Kadara (H)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. hkadara@mdanderson.org lwang22@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH